The role of receptor tyrosine kinase inhibition in treating gastrointestinal malignancy

Bibliography

• SCHENK PW, SNAAR-JAGALSKA BE: Signal perception and transduction: the role of protein kinases. Biochim. Biophys. Acta (1999) 1449:1–24.
   PubMed Web of Science ®Google Scholar
• LEVITZKI A, GAZIT A: Tyrosine kinase inhibition: An approach to drug development. Science (1995) 267:1782–1787.
   PubMed Web of Science ®Google Scholar
• TRAXLER P, BOLD G, BUCHDUNGER E et al.: Tyrosine kinase inhibitors: From rational design to clinical trials. Med. Res. Rev (2001) 21 (6):499–512.
   PubMed Web of Science ®Google Scholar
• RHOADS RE: Signal transduction pathways that regulate eukaryotic protein synthesis. J. Biol. Chem. (1999) 274.30337–30340.
   PubMed Web of Science ®Google Scholar
• PAWSON T: Protein modules and signalling networks. Nature (1995) 373:573–580.
   PubMed Web of Science ®Google Scholar
• HANKS SK, HUNTER T: The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. (1995) 9:576–596.
   PubMed Web of Science ®Google Scholar
• SEGER R, KREBS EG: The MAPK signaling cascade. FASEB J. (1995) 9:726–735.
   PubMed Web of Science ®Google Scholar
• BRAUN AP, SCHULMAN H: The multifunctional calcium/calmodulin dependent protein kinase: from form to function. Ann. Rev Physiol (1995) 57:417–445.
   PubMed Web of Science ®Google Scholar
• NIGG EA: Cyclin dependent protein kinases: key regulators of the eukaryotic cell cycle. Bioessays (1995) 17:471–480.
   PubMed Web of Science ®Google Scholar
• TREISMAN R: Regulation of transcription by MAP kinase cascades. Carr: Opin. Cell Biol. (1996) 8:205–215.
   PubMed Web of Science ®Google Scholar
• IHLE JN: Cytokine receptor signalling. Nature (1995) 377:591–594.
   PubMed Web of Science ®Google Scholar
• CLARK EA, BRUGGE JS: Integrins and signal transduction pathways: the road taken. Science (1995) 268:233–239.
   PubMed Web of Science ®Google Scholar
• GUAN K: The mitogen activated protein kinase signal transduction pathway: from the cell surface to the nucleus. Cell Signal. (1994) 6:581–589.
   PubMed Web of Science ®Google Scholar
• SHIOZAKI H, KADOWAKI T, DOKI Y et al: Effect of epidermal growth factor on cadherin-mediated adhesion in a human oesophageal cancer cell line. Br. J. Cancer (1995) 71:250–258.
   PubMed Web of Science ®Google Scholar
• MCINNES C, SYKES BD: Growth factor receptors: structure, mechanism and drug discovery. Biopolymers (1997) 43:339–366.
   PubMed Web of Science ®Google Scholar
• BOONSTRA J, RIJKEN P, HUMBEL B et al: The epidermal growth factor. Cell Biol. hat. (1995) 19:413–430.
   Web of Science ®Google Scholar
• KUMAR V, BUSTIN SA, MCKAY IA: Transforming growth factor alpha. Cell Biol. hat. (1995) 19:373–388.
   Web of Science ®Google Scholar
• YARDEN Y, SLIWKOWSKI MX: Untangling the ErbB signaling network. Nat. Rev Ma Cell Biol. (2001) 2:127–137.
   PubMed Web of Science ®Google Scholar
• QUIA X, DOUGALL WC, HELLMAN ME, GREENE MI: Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation. Oncogene (1994) 9(5):1507–1514.
   PubMed Web of Science ®Google Scholar
• CHEN W, KUNG H, YANG W, LIN W: Comparative tyrosine kinase profiles in colorectal cancers: enhanced arg expression in carcinoma as compared with adenoma and normal mucosa. Int. J. Cancer (1999) 83:579–584.
   PubMed Web of Science ®Google Scholar
• GRAUS-PORTA d, BEERLI RR, DALY JM: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. (1997) 16:1647–1655.
   PubMed Web of Science ®Google Scholar
• MOGHAL N, STERNBERG PW: Multiple positive and negative regulators of signaling by the EGF-receptor. Curt: Opin. Cell Biol. (1999) 11:190–196.
   PubMed Web of Science ®Google Scholar
• WELLS A: EGF Receptor. Int. J. Biochem. Cell Biol. (1999) 31:637–643.
   Google Scholar
• COHEN S, CARPENTER G, KING L Jr: Epidermal growth factor receptor-kinase interactions: Co-purification of receptor and epidermal growth factor enhanced phosphorylation activity. J. Biol. Chem. (1980) 255:4834–4842.
   PubMed Web of Science ®Google Scholar
• ALLEN LF, LENEHAN PF, EISEMAN IA, ELLIOTT WL, FRY DW: Potential benefits of the irreversible pan-erbB inhibitor, CI-1033 in the treatment of breast cancer. Semin. Oncol (2002) 29(3, Suppl. 11):11–21.
   Google Scholar
• JI GS, ERMINI S, BAULIDA J et al.: Epidermal growth factor signaling and mitogenesis in PLCgammal null mouse embryonic fibroblasts. Ma Biol. Cell (1998) 9:749–757.
   PubMed Web of Science ®Google Scholar
• NICHOLSON RI, GEE JMW, HARPER ME: EGFR and cancer prognosis. Eur: J. Cancer (2001) 37:S9–S15.
   PubMed Web of Science ®Google Scholar
• SALOMON DS, BRANDT R, CIARDIELLO F et al.: Epidermal growth factor related petides and their receptors in human malignancies. Crit. Rev. Oncol Hematol (1995) 19:183–232.
   PubMed Web of Science ®Google Scholar
• DERYNCK R, GOEDDEL DV, ULLRICH A et al.: Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res. (1987) 47:707–712.
   PubMed Web of Science ®Google Scholar
• KAWAMOTO TK, SATO JD, LEA et al:Growth stimulation of A431 cells by epidermal growth factor: I dentification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc. Natl. Acad. Sci. USA (1983) 80:1337–1341.
   PubMed Web of Science ®Google Scholar
• SATO JD, KAWAMOTO T, LE AD et al:Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mo/. Biol. Med. (1983) 1:511–529.
   PubMedGoogle Scholar
• HERBST RS, SHIN DM: Monoclonal antibodies to target epidermal growth factor receptor-positive tumors. Cancer (2002) 94:1593–1611.
   PubMed Web of Science ®Google Scholar
• HONG WK, ARQUETTE MA, NABELL L et al.: Efficacy and safety of the anti-epidermal growth factor antibody (EGFR) IMC-C225, in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc. ASCO (2001) 20:224a.
   Google Scholar
• BURTNESS BA, LI Y, FLOOD Wet al.: Phase III trial comparing cisplatin (C) + placebo to C + anti-epidermal growth factor antibody (EGFR) C225 in patients with metastatic/recurrent head and neck cancer (HNC). Proc. ASCO (2002) 21:226a.
   Google Scholar
• COHEN RB, FALCEY JW, PAULTER VJ et al.: Safety profile of the monoclonal antibody (MoAb) IMC-C225, an anti-epidermal growth factor receptor (EGFr) used in the treatment of EGFr positive tumors. Proc. ASCO (2000) 19:474a.
   Google Scholar
• HACKEL PO, ZWICK E, PRENZEL N et al.: Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Carr: Opin. Cell Biol. (1999) 11:184–189.
   PubMed Web of Science ®Google Scholar
• DUMAS J: Growth factor receptor kinase inhibitors: recent progress and clincal impact. Carr: Opin. Drug Discov. Bevel. (2001) 4:378–389.
   PubMedGoogle Scholar
• ••Excellent review of low molecular weightinhibitors being developed.
   Google Scholar
• DENNY WA: The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases. Farmaco (2001) 56:51–56.
   PubMedGoogle Scholar
• WOODBURN JR: The epidermal growthfactor receptor and its inhibition in cancer therapy. Pharmacol Ther. (1999) 82:241–250.
   PubMed Web of Science ®Google Scholar
• CIARDIELLO F: Epidermal growth factor receptor tyrosine kinase inhibitors as anti-cancer agents. Drugs (2000) 60:25–32.
   PubMed Web of Science ®Google Scholar
• CIARDIELLO F, CAPUTO R, BIANCO R et al: Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res. (2001) 7:1459–1465.
   PubMed Web of Science ®Google Scholar
• HIRATA A, OGAWA S, KOMETANI T et al.: ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res. (2002) 62:2554–2560.
   PubMed Web of Science ®Google Scholar
• CIARDIELLO F, CAPUTO R, BIANCO R et al: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. (2000) 6:2053–2063.
   PubMed Web of Science ®Google Scholar
• •Demonstrates the synergism of kinase inhibition and cytotoxic therapy.
   Google Scholar
• WOODBURN J, KENDREW J, FENNELL M, KELLY H, WAKELING A: ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): Correlation of c-fos expression and tumor growth inhibition. 91st American Association for Cancer Research Meeting, CA, USA (2000) (Abstract 2552).
   Google Scholar
• JO M, STOLZ DB, ESPLEN JE, DORKO K, MICHALOPOULOS GK, STROM SC: Cross-talk between epidermal growth factor receptor and c-met signal pathways in transformed cells. Biol. Chem. (2000) 275(12):8806–8811.
   Web of Science ®Google Scholar
• SIROTNAK FM, ZAKOWSKI ME MILLER VA et al.: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. (2000) 6:4885–4892.
   Google Scholar
• SWAISLAND H, LAIGHT A, STAFFORD L et al: Pharmacokinetics and tolerability of the orally active epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Pharmacokinet. (2001) 40:297–306.
   PubMed Web of Science ®Google Scholar
• KRIS M, RANSON M, FERRY D et al:Phase I study of oral ZD1839 (Iressa), a novel inhibitor of epidermal growth factor tyrosine kinase (EGFR-TK): evidence of good tolerability and activity. Clin. Cancer Res. (1999) 5(Suppl.):3749S.
   Google Scholar
• KRIS MG, NATALE RB, HERBST RS et al.: A Phase II trial of ZD1839 (Iressa) in advanced non-small cell lung cancer (NSCLC) patients who failed platinum-and docetaxel-based regimens (IDEAL2). Proc. Am. Soc. Gin. Oncol (2002) 21:292a.
   Google Scholar
• FUKOAKA M, YANO S, GIAC CONE G et al.: Final results from a Phase II trial of ZD1839 ('Iressa') for patients with advanced non-small cell lung cancer (IDEAL1). Proc. Am. Soc. Clin. Oncol (2002) 21:298a.
   Google Scholar
• MILLER VA, JOHNSON DH, HEELAN RT et al.: A pilot trial demonstrates the safety of ZD1839 (Iressa), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non small cell lung cancer. Proc. Am. Soc. Gin. Oncol (2001) 20:326a.
   Google Scholar
• POLLACK VA, SAVAGE DM, BAKER DA et al.: Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and anti-tumor effects in athymic mice. J. Pharmacol Exp. Ther. (1999) 291(2):739–748.
   PubMed Web of Science ®Google Scholar
• PEREZ-SOLER R, CHACHOUA A, HUBERMAN M et al.: A Phase II trial of the epidermal growth factor receptor (EGER) tyrosine kinase inhibitor OSI-774, following platinum based chemotherapy in patients with advanced EGFR expressing, non-small cell lung cancer (NSCLC). Proc. Am. Soc. Gin. Oncol (2001) 20:310a.
   Google Scholar
• SIU LL, SOULIERES D, SENZER N et al.: A Phase II, multi center study of the epidermal growth factor receptor (EGER) tyrosine kinase inhibitor (TKI), CP-358774, in patients with advanced squamous cell carcinomas of the head and neck (SCCHN). 1 1 th NCI-EORTC-AACR Symposium on New Drugs M Cancer Therapy Amsterdam, The Netherlands (2000) (Abstract 387).
   Google Scholar
• KITAGAWA Y, UEDA M, ANDO N, OZAWA S, SHIMIZU N, KITAJIMA M: Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin. Cancer Res. (1996) 2(5):909–914.
   PubMed Web of Science ®Google Scholar
• ITAKURA Y, SASANO H, SHIGA C et al.: Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathological findings and DNA amplification. Cancer (1994) 74(3):795–804.
   Google Scholar
• HIRAI T, KUWAHARA M, YOSHIDA K et al.: Clinical results of transhiatal esophagectomy for carcinoma of the lower thoracic esophagus according to biological markers. Dis. Esophagus (1998) 11:221–225.
   PubMedGoogle Scholar
• BRITO MJ, FILIPE MI, LINEHAN J, JANKOWSKI J: Association of transforming growth factor alpha and its precursors with malignant change in Barretts epithelium: biological and clinical variables. Int. J. Cancer (1995) 60:27–32.
   PubMed Web of Science ®Google Scholar
• TSUGAWA K, YONEMURA Y, HIRONO Y et al.: Amplification of the c-met, c-erbB2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. Oncology (1998) 55:475–481.
   PubMed Web of Science ®Google Scholar
• TAKITA M, ONDA M, TOKUNAGA A: Immunohistochemical demonstration of angiogenic growth factors and EGF receptor in hepatic metastases and primary human gastric cancer. Nippon Ika Daigaku Zasshi (1998) 65:358–366.
   PubMedGoogle Scholar
• YASUI W, HATA J, YOKOZAKI H et al: Interaction between epidermal growth factor and its receptor in progression of human gastric carcinoma. Int. Cancer (1988) 41:211–217.
   PubMed Web of Science ®Google Scholar
• JUNG YD, MANSFIELD PF, AKAGI M et al.: Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Ear: J. Cancer (2002) 38(8):1133–1140.
   PubMed Web of Science ®Google Scholar
• KLUFTINGER AM, ROBINSON BW, QUENVILLE NE FINLEY RI, DAVIS NL: Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer. Surg. Oncol (1992) 1:97–105.
   PubMedGoogle Scholar
• STEELE RJ, KELLY P, ELLUL B, EREMIN 0: Epidermal growth factor receptor expression in colorectal cancer. Br. Surg. (1990) 77:1352–1354.
   PubMed Web of Science ®Google Scholar
• DE JONG KP, STELLEMA R, KARRENBELD A et al: Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53 and Ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology (1998) 28:971–979.
   PubMed Web of Science ®Google Scholar
• MAYER A, TAKIMOTO M, FRITZ E, SCHELLANDER G, KOFLER K, LUDWIG H: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor and mdr gene expression in colorectal cancer. Cancer (1993) 71:2454–2460.
   PubMed Web of Science ®Google Scholar
• TAKEMURA K, OBARA T, OKANO S et al.: Immunohistochemical study on the expression of epidermal growth factor receptor (EGER) in human colorectal carcinomas. Nippon Shokakibyo Gakkai Zasshi (1991) 88:1177–1183.
   PubMedGoogle Scholar
• TORRANCE CJ, JACKSON PE, MONTGOMERY E et al.: Combinatorial chemoprevention of intestinal neoplasia. Nat. Med. (2000) 6(8):1024–1028.
   PubMedGoogle Scholar
• ••This combinatorial approach is animportant concept.
   Google Scholar
• RITLAND SR, GENDLER SJ, BURGART LJ et al.: Inhibition of epidermal growth factor receptor tyrosine kinase fails to suppress adenoma formation in APCmin mice but induces duodenal injury. Cancer Res. (2000) 60:4678–4681.
   PubMed Web of Science ®Google Scholar
• ROBERTS RB, MIN L, WASHINGTON MK et al.: Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc. Natl. Acad. Sci. USA (2002) 99(3):1521–1526.
   PubMed Web of Science ®Google Scholar
• KARNES W, WELLER S, ADJEI P et al: Inhibition of epidermal growth factor receptor kinase induces protease dependent apoptosis in human colon cancer cells. Gastroenterology (1998) 114:930–939.
   PubMed Web of Science ®Google Scholar
• SCHEVING LA, STEVENSON MC, TAYLOMO ORE JM, TRAXLER P, RUSSELL WE: Integral role of the EGF receptor in HGF-mediated hepatocyte proliferation. Biochem. Biophys. Res. Commun. (2002) 290(1):197–203.
   PubMed Web of Science ®Google Scholar
• SHAHEEN RM, AHMAD SA, LIU W et al.: Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br. J. Cancer (2001) 85(4):584–589.
   PubMed Web of Science ®Google Scholar
• SALTZ L, RUBIN M, HOCHSTER H et al.: Cetwdmab (IMC-225) puls irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGER). Proc. ASCO (2001) 20:3a.
   Google Scholar
• PAI R, SOREGHAN B, SZABO IL, PAVELKA M, BAATAR D, TARNAWSKI AS: Prostaglandin E2transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med. (2002) 8(3):289–293.
   PubMed Web of Science ®Google Scholar
• KINOSHITA T: Growth stimulation and induction of epidermal grwoth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells. Biochim. Biophys. Acta (1999) 1438:120–130.
   PubMed Web of Science ®Google Scholar
• COFFEY RJ: Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins and mitogenesis in polarizing colon cancer cells. Proc. Natl. Acad. Sci. USA (1997) 94:657–662.
   PubMed Web of Science ®Google Scholar
• OLAYIOYE MA: Update on Her-2 as a target for cancer therapy: Intracellular signaling pathways of erbB2/her2 and family members. Breast Cancer Res. (2001) 3:385–389.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, CLARK GM, WONG SG, LEVIN W, ULLRICH A, MCGUIRE RL: Human breast cancer: correlation of relapse and survival with amplification of the her-2/ neu oncogene. Science (1987) 235:177–182.
   PubMed Web of Science ®Google Scholar
• GUERIN A, BARROIS M, TERRIER MJ, SPIELMANN M, RIOU G: Overexpression of either c-myc or c-erbB-2/ neu protooncogene in human breast carcinomas; correlation with poor prognosis. Oncogene Res. (1988) 3:21–31.
   PubMedGoogle Scholar
• GIAI M, ROAGNA R, PONZONE R, DE BORTOLI M, DATI C, SISMONDI P: Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. Anti-Cancer Res. (1994) 14(3B):1441–1450.
   Google Scholar
• READ LD, KEITH D, SLAMON DJ, KATZENELLENBOGEN BS: Hormonal modulation of her-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell line. Cancer Res. (1990) 50:3947–3951.
   PubMed Web of Science ®Google Scholar
• PIETRAS RJ, ARBOLEDA J, REESE DM et al.: Her-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone dependent growth in human breast cancer cell. Oncogene (1995) 10:2435–2446.
   PubMed Web of Science ®Google Scholar
• DE LAURENTIS M, ARPINO G, MASSARELLI E et al.: A meta-analysis of the interaction between Her-2 and the response to endocrine therapy (ET) inn metastatic breast cancer (MBC). Proc. ASCO (2000) 19 (Abstract 301).
   Google Scholar
• MOKBEL K, HASSANALLY D: From her2 to herceptin. Can: Med. Res. Opin. (2001) 17(1):51–59.
   PubMed Web of Science ®Google Scholar
• SLAMON D, LEYLAND-JONES S, SHAK S et al.: Addition of herceptin (humanised anti-her2 antibody) to first line chemotherapy for her2 overexpressing metastatic breast cancer (HER2+/IVIBC) markedly increases anti-cancer activity: a randomised multinational controlled Phase III trial. Proc. ASCO (1998) 17:98a.
   Google Scholar
• COBLEIGH MA, VOGEL CL, TRIPATHY D et al.: Multinational study of the efficacy and safety of humanized anti-her2 monoclonal antibody in women who have her-2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.' Clin. Oncol. (1999) 17:2639–2648.
   Google Scholar
• BERNEY CR, FISHER RJ, YANG JL, RUSSELL PJ, CROWE PJ: Protein markers in colorectal cancer. Ann. Surg. (1999) 230:179–184.
   PubMed Web of Science ®Google Scholar
• KIM R, CLARKE MR, MELHEM MF et al.: Expression of p53, PCNA, and c-erbB-2 in Barretts metaplasia and adenocarcinoma. Dig. Dis. Sci. (1997) 42:2453–2462.
   PubMed Web of Science ®Google Scholar
• JANKOWSKI J, COGHILL G, HOPWOOD D, WORMSLEY KG: Oncogenes and onco-suppressor genes in adenocarcinoma of the oesophagus. Gut (1992) 33:1033–1038.
   PubMed Web of Science ®Google Scholar
• NAKAMURA T, NEKARDA H, HOELSCHER AH et al: Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barretts esophagus. Cancer (1994) 73: 1785-1794.
   Google Scholar
• HARDWICK RH, SHEPHERD NA, MOORGHEN M, NEWCOMB PV, ALDERSON D: C-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barretts oesophagus." Clin. Pathol. (1995) 48:129–132.
   PubMed Web of Science ®Google Scholar
• POLKOWSKI W, VAN SANDICK JW, OFFERHAUS GJ et al: Prognostic value of Lauren classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. Ann. Sur& Oncol. (1999) 6:290–297.
   PubMed Web of Science ®Google Scholar
• AL-KASSPOOLES M, MOORE JH, ORRINGER MB, BEER DG: Amplification and overexpression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. hat. J. Cancer (1993) 54:213–219.
   PubMed Web of Science ®Google Scholar
• HARDWICK RH, BARHAM CP, OZUA P et al.: Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis. Eur. Stow. Oncol. (1997) 23:30–35.
   PubMed Web of Science ®Google Scholar
• BAILEY T, BIDDLESTONE L, SHEPHERD N, BARR H, WARNER P, JANKOWSKI J: Altered radherin and catenin complexes in the Barretts esophagus - dysplasia - adenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am. J. Pathol. (1998) 152:135–144.
   PubMed Web of Science ®Google Scholar
• KANAI Y, OCHIAI A, SHIBATA T et al.: C-erbB-2 gene product directly associates with beta-catenin and plakoglobin. Biochem. Biophys. Res. Commun. (1995) 208(3):1067–1072.
   PubMed Web of Science ®Google Scholar
• SHIBATA T, OCHIAI A, KANAI Y et al: Dominant negative inhibition of the association between beta-catenin and c-erbB-2 by N-terminally deleted beta-catenin suppresses the invasion and metastasis of cancer cells. Oncogene (1996) 13(5):883–889.
   PubMed Web of Science ®Google Scholar
• YONEMURA Y, NINOMIYA I, YAMAGUCHI A et al: Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res. (1991) 51(3):1034–1038.
   PubMed Web of Science ®Google Scholar
• UCHINO S, TSUDA H, MARUYAMA K et al.: Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer (1992) 72(11):3179–3184.
   Google Scholar
• NAKAJIMA M, SAWADA H, YAMADA Y et al.: The prognostic significance of amplification and overexpression of c-met and c-erbB2 in human gastric carcinomas. Cancer (1999) 85(9):1894–1901.
   PubMed Web of Science ®Google Scholar
• TAKEHANA T, KUNITOMO K, KONO K et al.: Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immunosorbent assay. Int. J. Cancer (2002) 98:833–837.
   PubMed Web of Science ®Google Scholar
• KONO K, TAKAHASHI A, ICHIHARA F, SUGAI H, FUJII H, MATSUMOTO Y: Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res. (2002) 62:5813–5817.
   PubMed Web of Science ®Google Scholar
• KJELDSEN T, ANDERSEN AS, WIBERG FC et al.: The ligand specificites of the insulin receptor and the insulin-like growth factor receptor reside in different regions of a common binding site. Proc. Natl. Acad. Sci. USA (1991) 88:4404–4408.
   PubMed Web of Science ®Google Scholar
• BUSTIN SA, JENKINS PJ: The growth hormone-insulin like growth factor-I axis and colorectal cancer. Trends Mol Med. (2001) 7(10):447–454.
   PubMed Web of Science ®Google Scholar
• MACDONALD RS, PARK JHY, THORNTON WH: Insulin, IGF-I and IGF-II receptors in rat small intestine following massive small bowel resection. Dig. Dis. Sci. (1993) 38:1658–1669.
   PubMed Web of Science ®Google Scholar
• BRODT P, SAMANI A, NAVAB R: Inhibition of the Type I insulin-like growth factor receptor expression and signaling: novel strategies for antimetastatic therapy. Biocbem. Pbarmacol (2000) 60:1101–1107.
   PubMed Web of Science ®Google Scholar
• RUBIN R, BASERGA R: Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis and tumorigenicity. Lab. Invest. (1995) 73:311–331.
   Google Scholar
• BASERGA R: The IGF-I receptor in cancer research. Exp. Cell Res. (1999) 253:1–6.
   PubMed Web of Science ®Google Scholar
• RUBINI M, HONGO A, D'AMBROSIO C, BASERGA R: The IGF-I receptor in mitogenesis and transformation of mouse embryo cells: role of receptor number. Exp. Cell Res. (1997) 230:284–292.
   PubMed Web of Science ®Google Scholar
• DESBOIS-MOUTHON C, CADORET A, BLIVET VAN EGGELPOEL MJ et al: Insulin and IGF-1 stimulate the beta-catenin pathway through two signaling cascades involving GSK-3beta inhibition and ras activation. Oncogene (2001) 20:252–259.
   PubMed Web of Science ®Google Scholar
• WARREN RS, YUAN H, MATLI MR, FERRARA N, DONNER DB: Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J. Biol. Chem. (1996) 271:29483–29488.
   PubMed Web of Science ®Google Scholar
• DIPOPOLO A, MEMOLI A, APICELLA A et al.: IGF-II/IGF-I receptor pathway upregulates COX2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells. Oncogene (2000) 19:5517–5524.
   PubMed Web of Science ®Google Scholar
• WANG D, PATIL S, WENHUI L, HUMPHREY LE, BRATTAIN MG, HOWELL GM: Activation of the TGF alpha autocrine loop is downstream of IGF-I receptor activation during mitogenesis in growth factor dependent human colon carcinoma cells. Oncogene (2002) 21:2785–2796.
   PubMed Web of Science ®Google Scholar
• FREIER S, WEISS O, ERAN M etal.: Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut (1999) 44:704–708.
   Google Scholar
• HAKAM A, YEATMAN TJ, LU L etal.: Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum. Patbol (1999) 30(10):1128–1133.
   Google Scholar
• MICHELL NP, LANGMAN MJ, EGGO MC: Insulin-like growth factors and their binding proteins in human colonocytes: preferential degradation of insulin-like growth factor binding protein 2 in colonic cancers. Br: J. Cancer (1997) 76:60–66.
   Google Scholar
• ZENILMAN ME, GRAHAM W: Insulin-like growth Factor I receptor messenger RNA in the colon is unchanged during neoplasia. Cancer Invest. (1997) 15:1–7.
   PubMed Web of Science ®Google Scholar
• WU Y, YAKAR S, ZHAO L, HENNIGHAUSEN L, LEROITH D: Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res. (2002) 62:1030–1035.
   PubMed Web of Science ®Google Scholar
• WANG Y, SUN Y: Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis. Curr. Cancer Drug Targets (2002) 2(3):191–207.
   PubMed Web of Science ®Google Scholar
• COOPER CS, PARK M, BLAIR DG et al.: Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature (1984) 311:29–33.
   PubMed Web of Science ®Google Scholar
• MAULIK G, SHRIKHANDE A, KIJIMA T, MA PC, MORRISON PT, SALGIA R: Role of the hepatocyte growth factor receptor, c-met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev (2002) 13:41–59.
   PubMed Web of Science ®Google Scholar
• •Good review of current opinion on Met and malignancy.
   Google Scholar
• KERMORGANT S, WALKER F, HORMI K, DESSIRIER V, LEWIN MJ, LEHY T: Developmental expression and functionality of hepatocyte growth factor and c-met in human fetal digestive tissues. Gastroenterology (1997) 112(5):1635–1647.
   PubMed Web of Science ®Google Scholar
• PRAT M, NARSIMHAN RP, CREPALDI T, NICOTRA MR, NATALI PG, COMOGLIO PM: The receptor encoded by the human c-met oncogene is expressed in hepatocytes, epithelial cells and solid tumors. Int.j Cancer (1991) 49:323–328.
   PubMed Web of Science ®Google Scholar
• BAATAR D, JONES MK, PAIR et al: Selective cyclooxygenase-2 blocker delays healing of esophageal ulcers in rats and inhibits ulceration triggered c-met/ hepatocyte growth factor receptor induction and extracellular signal regulated kinase 2 activation. Am. J. Pathol (2002) 160(3):963–972.
   PubMed Web of Science ®Google Scholar
• STELLA MC, COMOGLIO PM: HGF: a multifunctional growth factor controlling cell scattering. hat. Biothem. Cell Biol. (1999) 31:1357–1362.
   PubMed Web of Science ®Google Scholar
• FURGE KA, ZHANG YVV, VANDE WOUDE GF: Met receptor tyrosine kinase: enhanced signalling through adapter proteins. Oncogene (2000) 19:5582–5589.
   PubMed Web of Science ®Google Scholar
• JEFFERS M, FISCELLA M, WEBB CP: The mutationally activated met receptor mediates motility and metastasis. Proc. Natl. Acad. ScL USA (1998) 95:14417–14422.
   PubMed Web of Science ®Google Scholar
• HISCOX S, JIANG WG: Association of the HGF/SF receptor, c-met with the cell-surface adhesion molecule, E-Cadherin, and catenins in human tumor cells. Biothem. Bioplays. Res. Comm. (1999) 261:406–411.
   PubMed Web of Science ®Google Scholar
• DAVIES G, JIANG WG, MASON MD: Cell-cell adhesion molecules and their associated proteins in bladder cancer cells and their role in mitogen induced cell-cell dissociation and invasion. Anti-Cancer Res. (1999) 19:547–552.
   PubMed Web of Science ®Google Scholar
• MONGA SPS, MARS WM, PEDIADITAKIS P et al.: Hepatocyte growth factor induces wnt-independent nuclear translocation of beta-catenin after met-beta-catenin dissociation in hepatocytes. Cancer Res. (2002) 62:2064–2071.
   PubMed Web of Science ®Google Scholar
• DANILKOVITCH-MIAGKOVA A, MIAGKOV A, SKEEL A, NAKAIGAWA N, ZBAR B, LEONARD EJ: Oncogenic mutants of ron and met receptor tyrosine kinases cause activation of the beta-catenin pathway. Mol Cell. Biol. (2001) 21(17):5857–5868.
   PubMed Web of Science ®Google Scholar
• LI G, SCHAIDER H, SATYMOORTHY K, HANAKAWA Y, HASHIMOTO K, HERLYN M: Downregulation of E-cadherin and desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene (2001) 20:8125–8135.
   PubMed Web of Science ®Google Scholar
• MIURA H, NISHIMURA K, TSUJIMURA A et al: Effects of hepatocyte growth factor on E-cadherin mediated cell-cell adhesion in DU145 prostate cancer cells. Urology (2001) 58:1064–1069.
   PubMed Web of Science ®Google Scholar
• TANNAPFEL A, YASUI W, YOKOZAKI H, WITTEKIND C, TAHARA E: Effect of hepatocyte growth factor on the expression of E- and P-cadherin in gastric carcinoma cell lines. Vircbows Arch. (1994) 425:139–144.
   PubMed Web of Science ®Google Scholar
• KERMORGANT S, APARICIO T, DESSIRIER V et al.: Hepatocyte growth factor induces colonic cancer cell invasiveness via enhanced motility and protease overproduction. Evidence for PI3kinase and PKC involvement. Carcinogenesis (2001) 22:1035–1042.
   Google Scholar
• CAMP RL, RIMM EB, RIMM DL: Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer (1999) 86:2259–2265.
   PubMed Web of Science ®Google Scholar
• GHOUSSOUB RA, DILLON DA, D'AQUILA T, RIMM EB, FEARON ER, RIMM DL: Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer (1998) 82:1513–1520.
   PubMed Web of Science ®Google Scholar
• PISTERS LL, TRONCOSO P, ZHAU HE et al.: C-met proto-oncogene expression in benign and malignant human prostate tissues. J. Urol. (1995) 154:293–298.
   PubMed Web of Science ®Google Scholar
• SUZUKI K, HAYASHI N, YAMADA Y et al.: Expression of the c-met proto-oncogene in human hepatocellular carcinoma. Hepatology (1994) 20:1231–1236.
   PubMed Web of Science ®Google Scholar
• SAEKI H, ODA S, KAWAGUCHI H et al: Concurrent overexpression of ets-1 and c-met correlates with a phenotype of high cellular motility in human esophageal cancer. Int. J. Cancer (2002) 98:8–13.
   PubMed Web of Science ®Google Scholar
• PORTE H, TRIBOULET JP, KOTELE VETS L et al.: Overexpression of stromelysin-3, BM-40/SPARC and Met genes in human esophageal carcinoma: implications for prognosis. Clin. Cancer Res. (1998) 4:1375–1382.
   Google Scholar
• PARK WS, OH RR, KIM YS et al.: Absence of mutations in the kinase domain of the met gene and frequent expression of Met and HGF/SF protein in primary gastric carcinomas. Apmis (2000) 108:195–200.
   PubMed Web of Science ®Google Scholar
• HEIDEMAN DA, SNIJDERS PJF, BLOEMENA E et al.: Absence of tpr-met and expression of c-met in human gastric mucosa and carcinoma. J. Pathol. (2001) 194:428–435.
   PubMed Web of Science ®Google Scholar
• BECKER KF, KELLER G, HOEFLER H: The use of molecular biology in diagnosis and prognosis of gastric cancer. Surg. Oncol. (2000) 9:5–11.
   PubMed Web of Science ®Google Scholar
• LIU C, PARK M, TSAO MS: Over-expression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas. Oncogene (1992) 7:181–185.
   PubMed Web of Science ®Google Scholar
• UMEKI K, SHIOTA G, KAWASAKI H: Clinical significance of c-met oncogene alterations in human colorectal cancer. Oncology (1999) 56:314–321.
   PubMed Web of Science ®Google Scholar
• BOON EMJ, VAN DER NEUT R, VAN DE WETERING M, CLEVERS H, PALS ST: Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res. (2002) 62:5126–5128.
   PubMed Web of Science ®Google Scholar
• BARDELLI A, LONGATI P, WILLIAMS TA et al.: A peptide representing the carboxyl terminal tail of the met receptor inhibits kinase activity and invasive growth. " Biol. Chem. (1999) 274:29274–29281.
   Google Scholar
• PARR C, HISCOX S, NAKAMURA T et al.: NK4, a new HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells. Lit. J. Cancer (2000) 85:563–570.
   PubMed Web of Science ®Google Scholar
• JIANG W, HISCOX S, PARR C et al.: Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in-vitro angiogenesis of human vascular endothelial cells. Gin. Cancer Res. (1999) 5:3695–3703.
   Web of Science ®Google Scholar
• MCMAHON G: VEGF receptor signalling in tumor angiogenesis. Oncologist (2000) 5\(Suppl. 1):3–10.
   Google Scholar
• •Reviews importance of VEGFR in malignancy.
   Google Scholar
• SHWEIKI D, ITIN A, SOFFER D et al.: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia initiated angiogenesis. Nature (1992) 359:843–845.
   PubMed Web of Science ®Google Scholar
• MINCHENKO A, BAUER T, SALCEDA S et al.: Hypoxic stimulation of vascular endothelial growth factor expression M vitro and in vivo. Lab. Invest. (1994) 71:374–379.
   PubMed Web of Science ®Google Scholar
• NEUFELD G, COHEN T, GENGRINOVITCH S et al.: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. (1999) 13:9–22.
   PubMed Web of Science ®Google Scholar
• BENJAMIN LE, KESHET E: Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc. Nati Acad. Sci. USA (1997) 94:8761–8766.
   PubMed Web of Science ®Google Scholar
• KUREBAYASHI J, OTSUKI T, KUNISUE H et al.: Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn. J. Cancer Res. (1999) 90:977–981.
   PubMedGoogle Scholar
• DROLLER MJ: Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Urol. (1998) 160:1932.
   Google Scholar
• KITAMURA M, TOI M, ARM K et al.: Concentrations of vascular endothelial growth factor in the sera of gastric cancer patients. Oncol. Rep. (1998) 5:1419–1424.
   PubMed Web of Science ®Google Scholar
• BALBAY MD, PETTAWAY CA, KUNIYASU H et al.: Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor. Clin. Cancer Res. (1999) 5:783–789.
   PubMed Web of Science ®Google Scholar
• AUVINEN MI, SIHVO El, RUOHTULA T et al.: Incipient angiogenesis in Barretts epithelium and lymphangiogenesis in Barretts adenocarcinoma.Oncol. (2002)20(13):2971–2979.
   Google Scholar
• YONEMURA Y, FUSHIDA S, BANDO E et al.: Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR) - 3 in gastric cancer. Ear: J. Cancer (2001) 37(7):918–923.
   PubMed Web of Science ®Google Scholar
• CASCINU S, STACCIOLI MP, GASPARINI et al.: Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin. Cancer Res. (2000) 6:2803–2807.
   PubMed Web of Science ®Google Scholar
• KABBINAVAR F, HURWITZ HI, FEHRENBACHER L et al.: Phase II, randomized trial comparing bevacizumab plus fluorouracil(FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Gin. Oncol. (2003) 21:60–65.
   Web of Science ®Google Scholar
• FONG TAT, SHAWVER LK, SUN Let al.: 5U5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. (1999) 59:99–106.
   Google Scholar
• SHAHEEN RM, DAVIS DW, LIU W et al.: Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res. (1999) 59:5412–5416.
   PubMed Web of Science ®Google Scholar
• ROSEN L, MULAY M, MAYERS A et al.: Phase I dose-escalating trial of 5U5416, a novel angiogenesis inhibitor in patients with advanced malignancies. J. Clin. Oncol. (1999) 18:161a.
   Google Scholar
• SCIGALLA P, HANNAH A, LANGECKER P et al.: First preclinical and clinical results with the antiangiogenetic substance SU5416 in malignancies. Eui: Cancer (1999) 35 (Supp1.5):S62a.
   Google Scholar
• ROSEN L, HANNAH A, ROSEN P et al: Phase I experience with oral 5U6668, a novel multiple receptor tyrosine kinase inhibitor in patients with advanced malignancies. 11th NCI-EORTC-AACR Symposium on new drugs M cancer therapy, Amsterdam, The Netherlands (2000) (Abstract 581).
   Google Scholar
• HENNEQUIN LF, THOMAS AP, JOHNSTONE C et al.: ZD6474: Design, synthesis and structure activity relationship of a novel, orally active VEGF receptor tyrosine kinase inhibitor. 92nd AACR meeting, LA, USA (2001) (Abstract 3152).
   Google Scholar
• WOOD JM, BOLD G, BUCHDUNGER E et al: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. (2000) 60:2178–2189.
   PubMed Web of Science ®Google Scholar
• BAKER CH, SOLORZANO CC, FIDLER IJ: Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res. (2002) 62:1996–2003.
   PubMed Web of Science ®Google Scholar
• MOASSER M, BASSO A, AVERBUCH S et al.: The tyrosine kinase inhibitor ZD1839 ('Iressa') inhibits HERZ driven signaling and suppresses the growth of HERZ overexpressing tumor cells. Cancer Res. (2001) 61:7184–7188.
   PubMed Web of Science ®Google Scholar
• McKAY JA, LOANE JF, ROSS VG et al: C-erbB-2 is not a major factor in the development of colorectal cancer. Br. Cancer (2002) 86:568–573.
   Google Scholar
• TAKAYAMA H, LaROCHELLE WJ, SHARP R et al.: Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc. Natl. Acad. Sci. USA (1997) 94:701–706.
   PubMed Web of Science ®Google Scholar
• MENDEL DB, LAIRD AD, XIN X et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin. Cancer Res. (2003) 9:327–337.
   PubMed Web of Science ®Google Scholar
• JOENSUU H, FLETCHER C, DIMITRIJEVIC S, SILBERMAN S, ROBERTS P, DEMETRI G: Management of malignant gastrointestinal stromal tumours. Lancet Onc. (2002) 3:655–664.
   PubMed Web of Science ®Google Scholar
• HIROTA S, ISOZAKI K, MORIYAMA Y et al.: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumours. Science (1998) 279:577–580.
   PubMed Web of Science ®Google Scholar
• RUBIN BP, SINGER S, TSAO C et al.: KIT activation is a ubiquitous feature of gastrointestinal stromal tumours. Cancer Res. (2001) 61:8118–8121.
   PubMed Web of Science ®Google Scholar
• DEMETRI GD, VON MEHREN M, BLANKE CD et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal tumors. N Engl. I Med. (2002) 347:472–480.
   PubMed Web of Science ®Google Scholar
• VAN OOSTEROM AT, JUDSON I, VERWEIJ J et aL:Safety and efficacy of imatinib (5T1571) in metastatic gastrointestinal stromal tumours: a Phase I study. Lancet (2001) 358:1421–1423.
   PubMed Web of Science ®Google Scholar
• http://www.cancerresearchuk.org/ aboutcancer/statistics/29375/29902 Website for Cancer research UK. Incidence and mortality figures. Updated October 2002.
   Google Scholar